→
Zimmer Biomet Holdings, Inc
Zimmer Biomet Holdings, Inc. (ZBH) currently trades at $93.12, with a market cap of $17.59B, reflecting a modest year-over-year revenue growth of 7.20%. While the company has consistently beaten earnings estimates in the last four quarters, the EPS growth of -20.07% raises concerns about its profitability trajectory. With a P/E ratio of 25.65, ZBH appears fairly valued, but the high P/B of 1.40 suggests limited upside potential in the near term.
Investors should adopt a neutral stance on ZBH, waiting for clearer signs of recovery in profitability before making substantial investments.
Zimmer Biomet’s Quarterly Earnings Preview: What You Need to Know
2026-04-10
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results
2026-04-09
Zimmer Biomet (ZBH) Valuation Check After New Technology Leadership And Robotic Shoulder Surgery Milestones
2026-04-09
Zimmer hires chief science, technology and medical affairs officer
2026-04-07
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes your holdings, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates ZBH as Neutral. Investors should adopt a neutral stance on ZBH, waiting for clearer signs of recovery in profitability before making substantial investments.
The significant decline in EPS growth at -20.07% could signal underlying issues in profitability, particularly if revenue growth does not translate into improved margins. Furthermore, with a beta of 0.59, ZBH shows lower volatility, but this could limit upside gains in a bullish market environment.
If Zimmer Biomet can leverage its new technology leadership and successful robotic shoulder surgery milestones, it may see a resurgence in demand, potentially driving future revenue growth beyond the current 7.20%. Additionally, a favorable analyst consensus with 3 Strong Buy ratings suggests optimism among experts for the company's long-term prospects.
Zimmer Biomet Holdings, Inc. (ZBH) currently trades at $93.12, with a market cap of $17.59B, reflecting a modest year-over-year revenue growth of 7.20%. While the company has consistently beaten earnings estimates in the last four quarters, the EPS growth of -20.07% raises concerns about its profitability trajectory. With a P/E ratio of 25.65, ZBH appears fairly valued, but the high P/B of 1.40 suggests limited upside potential in the near term.
Zimmer Biomet Holdings, Inc. (ZBH) currently trades at $93.12, with a market cap of $17.59B, reflecting a modest year-over-year revenue growth of 7.20%. While the company has consistently beaten earnings estimates in the last four quarters, the EPS growth of -20.07% raises concerns about its profitability trajectory. With a P/E ratio of 25.65, ZBH appears fairly valued, but the high P/B of 1.40 suggests limited upside potential in the near term. Our overall verdict is Neutral.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for ZBH at helmterminal.dev/analyze/ZBH, updated continuously during US market hours. No signup required.